Prostate cancer active surveillance

Modern up-to-date radiotherapy methods cause a man so few adverse effects that as a rule, there is no longer any need for active follow-up for prostate cancer.

What is active surveillance of prostate cancer?

Active surveillance has long been one of the treatment options for men with low-risk localised prostate cancer. Frequently, this option has been chosen, because the side effects of prostate cancer treatment have been thought to decrease a man’s quality of life during his lifetime more than the cancer itself would. While under active surveillance, the patient undergoes regular examinations and tests, and if the cancer shows any signs of advancing, the need for treatment will be re-evaluated.

Active surveillance or immediate treatment of prostate cancer?

Active surveillance, however, involves a risk of cancer progression, as one cannot know for sure, which of the localised cancers stay local, and which will possibly become aggressive and begin to spread. Even recent research results (Hamdy et al. 2016) have suggested that the active monitoring of prostate cancer is associated with higher incidences of disease progression and metastases than is immediate treatment. Regular surveillance biopsies also involve a risk of infection. Moreover, the high number of tests tend to increase the surveillance costs.

Today, the fact in favour of the immediate treatment of localised prostate cancer is that the use of modern tissue-internal or external radiotherapy minimises the adverse effects of the treatment. In other words, the man’s quality of life remains as good as possible, while simultaneously, it is possible to treat the cancer efficiently. The most advanced radiotherapy techniques have not even been found to involve a risk of secondary cancers.

Active surveillance at Docrates Cancer Center

If active surveillance is the best option, at Docrates Cancer Center it can be arranged individually tailored. In active surveillance, decisions are always made after a thorough discussion where the benefits and risks of surveillance are weighed. At Docrates, the discussion is attended by the patient and his family and close friends and, as necessary, a urologist and an oncologist, so that the overall understanding is as comprehensive as possible and the patient knows exactly what his situation is and how to proceed.

Active surveillance includes:

  • Regular examinations: PSA testing every few months, regular MRI scans and, if necessary, new biopsies
  • Reassessment of the need for treatment: If the patient’s PSA levels increase at a rapid rate, MRI scans show that the cancer is advancing or a new biopsy indicates that the prostate cancer has become more aggressive, the need for treatment will be reassessed together with the patient.

Read more

Accurate information on aggressiveness and tumor staging form the basis for prostate cancer treatment

In western countries, prostate cancer is the most common cancer type in men. In its early stages, it is often...

Read more

Should low-risk prostate cancer be left to active monitoring?

Active treatment vs. monitoring of localised low-risk prostate cancer has long been a contested topic. According to the results of...

Read more

Docrates uses the newest drug therapies for breast cancer

New cancer drugs are being developed all the time, and new uses are being found for drugs already in use....

Read more

“The future of cancer treatment” is already a reality in Finland – gene profiling may benefit all cancer patients

- Gene profiling is a new method for examining the characteristics of cancer tumors, which is currently useful in the...

Read more

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
358 10 773 2010

Contact us!

Mon-Thu 8 am-6 pm, Fri 8 am-4 pm (GMT +3)